Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services, Inc.

GRDNNYSE / NASDAQHealthcareSmall cap

$46.94+$0.27 (+0.6%)

Last close · Data as of Nov 20, 2026

Market cap
$2.6B
P/E
52.5x
EV / EBITDA
26.5x
Revenue
$1.4B
Net margin
3.4%
ROCE
28.9%

+69.8% over the last year

Guardian Pharmacy Services, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+12.1%
3M
+25.2%
6M
+24.7%
1Y
+69.8%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change +$0.27 (+0.6%) from $47 to $47 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GRDN, bought on each weekday since 2024.

News & filings

What Guardian Pharmacy Services filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was more than a hundred times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.

Read moreShow less

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.

Sector
Healthcare
Shares outstanding
62.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.6B
P/E
52.5x
P/B
12.6x
EV / EBITDA
26.5x
EV / Sales
1.8x
P/S
1.8x
52-week high
$50.33
52-week low
$27.03

Profitability

Operating margin
5.0%
Net margin
3.4%
EBITDA margin
6.7%
ROE
23.9%
ROCE
28.9%
ROIC
26.1%
ROA
11.9%
Asset turnover
3.51

Growth

Revenue
$1.4B
Revenue growth, 1Y
17.9%
Revenue CAGR, 3Y
16.8%
Net profit growth, 1Y
-156.4%
Free cash flow
$80.7M

Solvency

Current ratio
1.38
Debt / Equity
0.18
Debt / Assets
0.09
CFO / Net profit
2.04
Cash / Market cap
2.5%

Where the revenue went

Of every $100 of FY2025 revenue, $3 was left as net income.

Guardian Pharmacy Services, Inc. income statement flow, FY2025
Guardian Pharmacy Services, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.2B
RevenueGross profit$292.7M
Gross profitOperating expenses$220.0M
Gross profitOperating income$72.7M
Operating incomePretax income$72.7M
Interest and other incomePretax income$720.0k
Pretax incomeTax and other$24.2M
Pretax incomeNet income$49.2M

Revenue and net profit

Revenue grew 17.9% in FY2025; net profit is the dashed line.

Guardian Pharmacy Services, Inc. revenue and net profit by fiscal year
Guardian Pharmacy Services, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$908.9M$35.4M
FY2023$1.0B$23.9M
FY2024$1.2B-$87.3M
FY2025$1.4B$49.2M

Cash flows

FY2025: $100.3M from operations, $80.7M free after investment (dashed).

Guardian Pharmacy Services, Inc. operating and free cash flow by fiscal year
Guardian Pharmacy Services, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$48.5M$31.8M
FY2023$70.8M$56.3M
FY2024$58.0M$41.6M
FY2025$100.3M$80.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.4B+17.9%1Y
EBITDA
$96.4M
Net profit
$49.2M
Cash from operations
$100.3M+73.0%1Y
Free cash flow
$80.7M+94.1%1Y
Revenue CAGR, 3Y
16.8%
Net profit CAGR, 3Y
11.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.4B$96.4M$49.2M$80.7M23.9%+17.9%-156.4%

Monthly returns

Month-by-month returns of GRDN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$412.7M
Liabilities$194.7M
Equity$217.9M
Paid-in capital$139.3M
Retained earnings$66.3M
Minority interest$12.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GRDN highlighted.

P/E against peers

GRDN trades at 52.5x earnings against a peer median of -17.9x.

  1. Guardian Pharmacy Services, Inc. (this company)52.5x

Not shown (no positive earnings and no EV / Sales): Disc Medicine, Inc., Definium Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Guardian Pharmacy Services, Inc.GRDNthis company$2.6B52.5x12.6x23.9%26.5x
Soleno Therapeutics, Inc.SLNO$2.8B132.3x6.1x4.6%96.7x
Arcutis Biotherapeutics, Inc.ARQT$2.7B-170.1x14.5x-8.5%1582.5x
Disc Medicine, Inc.IRON$2.7B-12.8x3.7x-28.7%-12.8x
Definium Therapeutics, Inc.DFTX$2.7B-14.6x8.1x-55.3%-13.8x
Alumis Inc.ALMS$2.6B-10.7x8.6x-80.8%-5.7x
Tarsus Pharmaceuticals, Inc.TARS$2.6B-39.1x7.6x-19.3%-45.8x
IDEAYA Biosciences, Inc.IDYA$2.6B-22.6x2.5x-11.1%-16.0x
Heartflow, Inc.HTFL$2.5B-21.3x8.3x-38.8%-26.4x
Peer median—-17.9x7.8x-24.0%-13.3x

Year-to-date ROI

GRDN since 1 January, against earlier years.

Historical volatility

GRDN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Guardian Pharmacy Services, Inc. operating margin by fiscal year
Guardian Pharmacy Services, Inc. operating margin by fiscal year
DateOperating margin
FY20225.7%
FY20233.9%
FY2024-5.1%
FY20255.0%
LineFY2025
Cost of revenueCost Of Revenue$1.2B
Gross profitGross Profit$292.7M
Operating expensesOperating Expense$220.0M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$1.4B
Pretax incomePretax Income$73.4M

Learn while you research

Academy chapters picked for Guardian Pharmacy Services, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 52.5, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →